Disease versus disease: How one disease may ameliorate another

Pediatrics

Volumn 117, Issue 1, 2006, Pages 184-191

  Stiehm, E Richard ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Agammaglobulinemia; HIV; Receptor deficiency; Starvation; Vaccination

Indexed keywords

CHEMOKINE RECEPTOR; FINASTERIDE; IMMUNOGLOBULIN; RH IMMUNOGLOBULIN; SMALLPOX VACCINE; UNCLASSIFIED DRUG;

CELIAC DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DIARRHEA; DISEASE SEVERITY; EPSTEIN BARR VIRUS; ERYTHROCYTE DISORDER; GENE MUTATION; GENETIC RESISTANCE; GLUTEN FREE DIET; HEPATITIS G VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; KETOGENIC DIET; LEPROSY; MALARIA; MALNUTRITION; MEASLES; NEPHROSIS; PARVOVIRUS; PLASMODIUM VIVAX; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PSORIASIS; REVIEW; SMALLPOX; SYSTEMIC DISEASE; TUBERCULOSIS; X LINKED AGAMMAGLOBULINEMIA; GENERAL ASPECTS OF DISEASE; IMMUNITY;

DISEASE; HUMANS; IMMUNITY;

EID: 33644836690     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2004-2773     Document Type: Review

References (92)

1. Jenner E. An Enquiry Into the Causes and Effect of the Variolae Vaccinae. London, United Kingdom: Sampson-Low; 1778
2. Henderson DA, Moss B. Smallpox and vaccinia. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, PA: WB Saunders; 1999:74-95
3. Haldane JBS. The rate of mutation of human genes. Hereditas. 1948;35(suppl):267-273
4. Weatherall DJ. Thalassaemia and malaria, revisited. Ann Trop Med Parasitol. 1997;91:885-890
5. Luzzatto L. Genetics of red cells and susceptibility to malaria. Blood. 1997;54:961-976
6. Nagel RL, Roth EF Jr. Malaria and red cell genetic defects. Blood. 1989;74:1213-1221
7. Lell B, May J, Schmidt-Ott RJ, et al. The role of red blood cell polymorphisms in resistance and susceptibility to malaria. Clin Infect Dis. 1999;28:794-799
8. Meindl RS. Hypothesis: a selective advantage for cystic fibrosis heterozygotes. Am J Phys Anthropol. 1987;74:39-45
9. Crawford MDA. A genetic study, including evidence for heterosis, of cystic fibrosis of the pancreas. Heredity. 1972;29:126
10. Wood RE, Boat TF, Doershuk CR. Cystic fibrosis. Am Rev Respir Dis. 1976;113:833-878
11. O'Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology on nontuberculous mycobacterial diseases in the United States: results from a national survey. Am Rev Respir Dis. 1987;135:1007-1014
12. Boxerbaum B. Isolation of rapidly growing mycobacteria in patients with cystic fibrosis. J Pediatr. 1980;96:689-691
13. Smith MJ, Efthimiou J, Hodson ME, Batten JC. Mycobacterial isolations in young adults with cystic fibrosis. Thorax. 1984;39:369-375
14. Ebert DL, Olivier KN. Nontuberculous mycobacteria in cystic fibrosis. Infect Dis Clin North Am. 2002;16:221-233
15. Quinton PM. Abnormalities in electrolyte secretion in cystic fibrosis sweat glands due to decreased anion permeability. In: Quinton PM, Martinez JR, Hopfer U, eds. Fluid and Electrolyte Abnormalities in Exocrine Glands in Cystic Fibrosis. San Francisco, CA: San Francisco Press; 1983:51-74
16. Ma T, Thiagarajah JR, Yang H, et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest. 2002;110:1651-1658
17. Thiagarajah JR, Broadbent T, Hseih E, Verkman AS. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology. 2004;126:511-519
18. Stephens JC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet. 1998;62:1507-1515
19. Faulkner GC, Burrows SR, Khanna R, Moss DJ, Bird AG, Crawford DH. X-linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J Virol. 1999;73:1555-1564
20. Gratama JW, Oosterveer MAP, Zwann FE, Lepoutre J, Klein G, Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci USA. 1998;85:8693-8696
21. van Esser JW, Niesters HG, Van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364-4369
22. Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant. 2003;17:417-422
23. Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350:586-597
24. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to Parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med. 1994;330:1192-1196
25. Bray RS. The susceptibility of Liberians to the Madagascar strain of Plasmodium vivax. J Parasitol. 1958;44:371-373
26. Spencer HC, Miller LH, Collins WE, et al. The Duffy blood group and resistance to Plasmodium vivax in Honduras. Am J Trop Med Hyg. 1978;27:664-670
27. Miller LH, Mason SJ, Dvorak JA, McGinniss MH, Rothman IK. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science. 1975;189:561-563
28. Cole-Tobian JL, Cortes A, Baisor M, et al. Age-acquired immunity to a Plasmodium vivax invasion ligand, the Duffy binding protein. J Infect Dis. 2002;186:531-539
29. Hamblin MT, Di Rienzo A. Detection of the signature of natural selection in humans: evidence from the Duffy blood group locus. Am J Hum Genet. 2000;66:1669-1679
30. Lin-Fu JS. Prevention of Hemolytic Disease of the Fetus and Newborn Due to Rh Immunization. Rockville, MD: Public Health Services; 1975:1-20. US Department of Health, Education, and Welfare Publication No. 75 5125
31. Landsteiner K, Wiener AS. An agglutinable factor in human blood recognized by immune sera for Rhesus blood. Proc Soc Exp Biol Med. 1940;43:223
32. Levine P, Burnham L, Katzin EM, Vogel P. The role of isoimmunization in the pathogenesis of erythroblastosis fetalis. Am J Obstet Gynecol. 1941;42:925-937
33. Levine P. Serological factors as possible causes in spontaneous abortions. Heredity. 1943;34:71-80
34. Ascari WQ, Levine P, Pollack W. Incidence of maternal Rh immunization by ABO compatible and incompatible pregnancies. Br Med J. 1969;1(641):399-401
35. Finn R, Clarke CA, Donohoe WTA, et al. Experimental studies on the prevention of Rh haemolytic disease. Br Med J. 1961;5238:1486-1490
36. Freda VJ, Gorman JG. Antepartum management of Rh hemolytic disease. Bull Sloane Hosp Women Columbia Presbyt Med. 1962;8:147-155
37. Freda VJ, Gorman JG, Pollack W. Prevention of Rh-hemolytic disease with Rh-immune globulin. Am J Obstet Gynecol. 1977;128:456-460
38. Sandler SG. Intravenous Rh immune globulin for treating immune thrombocytopenic purpura [published correction appears in Curr Opin Hematol. 2002;9:179]. Curr Opin Hematol. 2001;8:417-420
39. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD. Familial incomplete male pseudohermaphrodism type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 1974;291:944-949
40. Imperato-McGinley J, Guerrero I, Gautier T, Peterson RE. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186:1213-1215
41. Mendonca BB, Inacio M, Costa EMF, et al. Male pseudohermaphroditism due to steroid 5α-reductase 2 deficiency: diagnosis, psychological evaluation and management. Medicine (Baltimore). 1996;75:64-76
42. Stoner E. The clinical development of a 5 alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol. 1990;37:375-378
43. Rittmaster RS. Finasteride. N Engl J Med. 1994;330:120-125
44. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-224
45. Libecco JF, Bergfeld WF. Finasteride in the treatment of alopecia. Expert Opin Pharmacother. 2004;5:933-940
46. Bayram F, Muderris I, Guven M, Ozcelik B, Kelestimur F. Low-dose (2.5 mg/day) finasteride treatment in hirsutism. Gynecol Endocrinol. 2003;17:419-422
47. Blumberg RW, Cassady HA. Effect of measles on the nephrotic syndrome. Am J Dis Child. 1947;73:151-166
48. Janeway CA, Hutchins Moll G, Armstron SH Jr, Wallace WM, Hallman N, Barness LA. Diuresis in children with nephrosis: comparison of response to injection of normal human serum albumin and to infection, particularly measles. Trans Assoc Am Physicians. 1948;61:108-111
49. Lin C-Y, Hsu H-C. Histopathological and immunological studies in spontaneous remission of nephrotic syndrome after intercurrent measles infection. Nephron. 1986;42:110-115
50. Starr S, Berkovich S. Effects of measles, gamma-globulin-modified measles and vaccine measles on the tuberculin test. N Engl J Med. 1964;270:386-391
51. Flick JA. Does measles really predispose to tuberculosis? Am Rev Respir Dis. 1976;114:257-265
52. Manfredi R, Coronado OV, Mastroianni A, Chiodo F. Concurrent infectious mononucleosis and measles: a potentially life-threatening association sharing underlying immunodeficiency. Pediatr Infect Dis J. 2003;22:470-471
53. Fost NC, Esterly NB. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr. 1968;72:351-357
54. Nagabhushanam P. Case report of psoriasis with rheumatoid arthritis with polyneuritic leprosy. Indian J Dermatol Venereol Leprol. 1969;35:97-98
55. Sugathan P, Riyaz N. First report of leprosy and psoriasis occurring together. Int J Dermatol. 1990;29:531-532
56. Kumar B, Raychaudhuri SP, Vossough S, Farber EM. The rare coexistence of leprosy and psoriasis. Int J Dermatol. 1992;31:551-554
57. Dogra S, Kaur I, Kumar B. Leprosy and psoriasis: an enigmatic relationship. Int J Lepr Other Mycobact Dis. 2003;71:341-344
58. van Berge-Henegouwen GP, Mulder CJJ. Pioneer in the gluten free diet: Willem-Karel Dicke 1905-1962, over 50 years of gluten free diet. Gut. 1993;34:1473-1475
59. Dicke WK. Coeliac Disease: Investigation of the Harmful Effects of Certain Types of Cereal on Patients With Coeliac Disease [thesis; in Dutch]. Utrecht, Netherlands: University of Utrecht; 1950
60. Dicke WK, Weijers HA, van de Kamer JH. Coeliac disease II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr. 1953;42:34-42
61. Guelpa G, Marie A. La lutte contre l'epilesie par la desintoxication et par la reeducation alimentaire. Rev Ther Med Chir. 1911;78:8-13
62. Wilder RM. The effect of ketonemia on the course of epilepsy. Mayo Clinic Bull. 1921;2:307
63. Peterman MG. The ketogenic diet in epilepsy. JAMA. 1925;84:1979-1983
64. Swink TC, Vining EPG, Freeman JM. The ketogenic diet: 1997. Adv Pediatr. 1997;44:297-329
65. Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology. 1971;21:1097-1103
66. Kossoff EH, Krauss GL, McGrogan JR, Freeman JM. Efficacy of the Atkins diet as therapy for intractable epilepsy. Neurology. 2003;61:1789-1791
67. Heilbronn LK, Ravussin E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am J Clin Nutr. 2003;78:361-369
68. Willi SM, Martin K, Datko FM, Brant BP. Treatment of type 2 diabetes in childhood using a very-low-calorie diet. Diabetes Care. 2004;27:348-353
69. Lentine K, Wrone EM. New insights into protein intake and progression of renal disease. Curr Opin Nephrol Hypertens. 2004;13:333-336
70. Russell RI. Review article: dietary and nutritional management of Crohn's disease. Aliment Pharmacol Ther. 1991;5:211-226
71. Harder H, Dineses B, Astrup A. The effect of a rapid weight loss on lipid profile and glycemic control in obese type 2 diabetic patients. Int J Obes Relat Metab Disord. 2004;28:180-182
72. Wright JJ, Birx DL, Wagner DK, Waldmann TA, Blaese RM, Fleisher TA. Normalization of antibody responsiveness in a patient with common variable hypogammaglobulinemia and HIV infection. N Engl J Med. 1987;317:1518-1520
73. Morell A, Barandun S, Locher G. HTLV-III seroconversion in a homosexual patient with common variable immunodeficiency. N Engl J Med. 1986;315:456-457
74. Webster AD, Lever A, Spickett G, Beattle R, North M, Thorpe R. Recovery of antibody production after HIV in "common" variable hypogammaglobulinemia. Clin Exp Immunol. 1989;77:309-313
75. Jolles S, Tyrer M, Johnson M, Webster D. Long term recovery of IgG and IgM production during HIV infection in a patient with common variable immunodeficiency (CVID). J Clin Pathol. 2001;54:713-715
76. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1966;86:367-377
77. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet. 1998;352:866-870
78. Pasi KJ, Sabin CA, Jenkins PV, Devereux HL, Ononye C, Lee CA. The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia. Br J Haematol. 2000;111:136-142
79. Travers K, Mboup S, Marlink R, et al. Natural protection against HIV-1 infection provided by HIV-2 [published correction appears in Science. 1995;268:1833]. Science. 1995;268:1612-1615
80. Travers KU, Eisen RG, Marlink RG, et al. Protection from HIV-1 infection by HIV-2. AIDS. 1998;12:224-225
81. Kokkotou EG, Sankale J-L, Mani I, et al. In vitro correlates of HIV-2-mediated HIV-1 protection. Proc Natl Acad Sci USA. 2000;97:6797-6802
82. Shea A, Sarr DA, Jones N, et al. CCR5 receptor expression is down-regulated in HIV type 2 infection: implication for viral control and protection. AIDS Res Hum Retroviruses. 2004;20:630-635
83. Stapleton JT. GB virus type C/hepatitis G virus. Semin Liver Dis. 2003;23:137-148
84. Maggi F, Tempestini E, Lanini L, et al. Blood levels of TT virus following immune stimulation with influenza or hepatitis B vaccine. J Med Virol. 2005;75:358-365
85. Buchbinder S, Vittinghoff E. HIV-infected long-term nonprogressors: epidemiology, mechanisms of delayed progression, and clinical and research implications. Microbes Infect. 1999;1:1113-1120
86. Heringlake S, Ockenga J, Tillmann HL, et al. GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis. 1998;177:1723-1726
87. Toyoda H, Fukuda Y, Hayakawa T, Takamatsu J, Saito H. Effect of GB virus coinfection on the course of HIV infection in hemophilia patients in Japan. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:209-213
88. Lefrere JJ, Roudot-Thoraval F, Morand-Joubert L, et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic and clinical progression of human immunodeficiency virus disease in coinfected persons. J Infect Dis. 1999;179:783-789
89. Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infection patients. N Engl J Med. 2001;345:715-724
90. Williams CR. Klinzman D, Yamashita TE, et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med. 2004;350:981-990
91. Bollinger RC, Gupta A. GB virus type C: A virus in search of a disease or a role in HIV therapy. Clin Infect Dis. 2004;38:410-411
92. Pomerantz RJ, Nunnari G. HIV and GB virus: can two viruses be better than one? N Engl J Med. 2004;350:963-965